Blood, Lymphatic, Or Bone Marrow Origin Or Derivative Patents (Class 435/372)
-
Publication number: 20130052676Abstract: The present invention relates to mast cell cultures that are derived from hematopoietic progenitors and the use thereof. The invention describes a method for generating in-vitro cultures of human mast cells with functional phenotype of connective tissue-type mast cells. By monitoring the levels of chemokines released into the medium, such mast cell cultures can be used as a cell-based assay to assess regulation of mast cell functions and pharmacological activities of tryptase inhibitors.Type: ApplicationFiled: August 28, 2012Publication date: February 28, 2013Inventors: See-Ying TAM, Yee San Issan TAM, Hang Yung Alaster LAU
-
Patent number: 8383604Abstract: The invention relates to methods and uses of modulating fetal hemoglobin expression (HbF) in a hematopoietic progenitor cells via inhibitors of BCL11A expression or activity, such as RNAi and antibodies.Type: GrantFiled: September 14, 2009Date of Patent: February 26, 2013Assignees: Children's Medical Center Corporation, President and Fellows of Harvard CollegeInventors: Stuart H. Orkin, Vijay G. Sankaran
-
Patent number: 8383095Abstract: The present disclosure relates to the field of hematopoietic stem cell transplantation. More specifically, methods, compositions and kits for improving engraftment of stem cell transplants by administering myeloid progenitor cells are provided.Type: GrantFiled: February 14, 2007Date of Patent: February 26, 2013Assignee: Cellerant Therapeutics, Inc.Inventors: Julie Lynne Christensen, Holger Karsunky
-
Patent number: 8383403Abstract: In one aspect of the present disclosure there is provided a method for preparing reticulocyte mimetics. In another aspect of the present disclosure there are provided reticulocyte mimetics obtained using the method. In yet another aspect of the present disclosure there is provided a whole blood reference control including the reticulocyte mimetics as provided. In still another aspect of the present disclosure there is provided a composition useful for preparing reticulocyte mimetics.Type: GrantFiled: May 5, 2010Date of Patent: February 26, 2013Assignee: Shenzhen Mindray Bio-Medical Electronics Co., Ltd.Inventors: Lu Wang, Zuyue Xu, Tao Xia
-
Patent number: 8383404Abstract: The present invention relates to methods of identifying, collecting and isolating hematopoietic stem cells (HSCs) and compositions of purified HSCs. Specifically, the present invention provides methods of isolating and purifying CD150+ HSCs, CD48? HSCs, and CD244? HSCs. The present invention also relates to purified cell samples with enriched CD150+ HSCs, CD48? HSCs, and CD244? HSCs populations, as well as methods of treating subjects with such compositions.Type: GrantFiled: January 24, 2011Date of Patent: February 26, 2013Assignee: The Regents of the University of MichiganInventors: Omer H. Yilmaz, Mark J. Kiel, Sean Morrison, Toshihide Iwashita
-
Publication number: 20130045539Abstract: The invention relates to a set of genetic constructs which comprises at least a first recombinogenic construct (i) with at least two portions homologous to the genomic regions preceding and following the DNA target site of a site specific endonuclease and also comprising both a negative selection and positive selection mark interposed with the homologous portions as well as a region into which a sequence of interest can be cloned adjacent to the positive selection marker; and a second construct (ii, iii or iv) comprising the meganuclease. The present invention also relates to a kit comprising these constructs and methods to use this set of constructs to introduce into the genome of a target cell, tissue or organism a sequence of interest.Type: ApplicationFiled: February 18, 2011Publication date: February 21, 2013Applicant: CELLECTISInventors: Christophe Delenda, Jean-Pierre Cabaniols
-
Patent number: 8377432Abstract: A method of neochondrogenesis, where following microfracture surgery or subchondral drilling, includes administering injections of an effective amount of a composition to the damaged, affected connective tissue, for example knee joint cartilage. The composition includes a mixture of hyaluronic acid combined with harvested stem cells, for example autologous peripheral blood-derived stem cells.Type: GrantFiled: April 14, 2010Date of Patent: February 19, 2013Inventor: Khay-Yong Saw
-
Publication number: 20130040829Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: August 13, 2012Publication date: February 14, 2013Applicant: University of Central Florida Research Foundation, Inc.Inventors: Pappachan E. Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajoti Deb
-
Patent number: 8372638Abstract: Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human ?1-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells.Type: GrantFiled: July 9, 2010Date of Patent: February 12, 2013Assignee: Zoltan Laboratories LLCInventor: Zoltan Kiss
-
Patent number: 8372579Abstract: The invention features methods for separating cells from a sample (e.g., separating fetal red blood cells from maternal blood). The method begins with the introduction of a sample including cells into one or more microfluidic channels. In one embodiment, the device includes at least two processing steps. For example, a mixture of cells is introduced into a microfluidic channel that selectively allows the passage of a desired type of cell, and the population of cells enriched in the desired type is then introduced into a second microfluidic channel that allows the passage of the desired cell to produce a population of cells further enriched in the desired type. The selection of cells is based on a property of the cells in the mixture, for example, size, shape, deformability, surface characteristics (e.g., cell surface receptors or antigens and membrane permeability), or intracellular properties (e.g., expression of a particular enzyme).Type: GrantFiled: May 8, 2007Date of Patent: February 12, 2013Assignee: The General Hospital CorporationInventors: Mehmet Toner, George Truskey, Ravi Kapur
-
Patent number: 8372797Abstract: Methods, cells and compositions of matter are provided for treatment of erectile dysfunction using stem cell therapy. In particular, various stem cells are modified or administered freshly isolated in order to induce smooth muscle regeneration, neural regeneration, and restoration of endothelial function. In some embodiments endogenous stem cells are mobilized or activated to achieve therapeutic benefit. In other embodiments compositions derived from stem cells are utilized for treatment of erectile dysfunction.Type: GrantFiled: June 22, 2007Date of Patent: February 12, 2013Assignee: Creative Medical Health, Inc.Inventor: Thomas E. Ichim
-
Patent number: 8372657Abstract: According to various embodiments, a microfluidic system for detecting a biological entity in a sample volume is provided. The microfluidic system may include: a chamber configured to receive the sample volume, wherein the chamber includes a detection region for detecting the biological entity; a first port in fluid communication with the chamber; and a second port including a filter in fluid communication with the chamber; and wherein a fluid provided to the first port or the second port flows between the first port and the second port through the chamber.Type: GrantFiled: October 20, 2010Date of Patent: February 12, 2013Assignee: Agency For Science, Technology, and ResearchInventors: Julien Reboud, Linus Tzu-Hsiang Kao, Andre Yao-Kuang Chung, Shin Yun Ng, Yu Chen, Yan Ping Wang, Janice Hao Yuan Liaw, Kum Cheong Tang
-
Publication number: 20130034901Abstract: The present invention relates to a stem cell and/or a population thereof having a specific profile of cell surface proteins and/or proteoglycans. The present invention also relates to use of a proteolytic enzyme in the modification of the cell surface of a stem cell. The present invention further relates to a method of modifying the cell surface of a stem cell by treatment with a proteolytic enzyme.Type: ApplicationFiled: April 6, 2011Publication date: February 7, 2013Applicant: SUOMEN PUNAINEN RISTI VERIPALVELUInventors: Johanna Nystedt, Tanja Hakkarainen, Petri Lehenkari, Erja Kerkelä, Leena Valmu
-
Patent number: 8367405Abstract: The present invention relates to the use of tissue non-specific alkaline phosphatase (TNAP) as a marker for identifying and/or isolating adult multipotential cells. The present invention also relates to cell populations enriched by methods of the present invention and therapeutic uses of these cells.Type: GrantFiled: April 12, 2006Date of Patent: February 5, 2013Assignee: Mesoblast, Inc.Inventors: Stan Gronthos, Andrew Christopher William Zannettino, Paul John Simmons
-
Patent number: 8367057Abstract: The present invention relates to stem cells suitable for transplantation and to methods for their preparation.Type: GrantFiled: February 21, 2011Date of Patent: February 5, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: Tsvee Lapidot, Joy Kahn
-
Publication number: 20130028915Abstract: Compositions and methods for eliciting therapeutic immunity and improving clinical outcomes in patients with pancreatic cancer are disclosed herein. The present invention describes a dendritic cell (DC)-vaccine comprising DCs pulsed with peptides derived from pancreatic cancer antigens for the therapy against pancreatic cancer. The vaccine described herein is safe, and leads to expansion of cancer specific T cells in patients with pancreatic cancer.Type: ApplicationFiled: July 27, 2012Publication date: January 31, 2013Applicant: BAYLOR RESEARCH INSTITUTEInventors: Anna Karolina Palucka, Jacques F. Banchereau, Hideki Ueno
-
Patent number: 8362206Abstract: The present invention provides a chimeric protein capable of killing or modifying a cell expressing abnormally high levels of a ligand of a receptor of the TNF/NGF family, comprising the amino acid sequence of at least one polypeptide consisting of an extracellular portion of said receptor connected to an effector molecule. In addition the invention provides pharmaceutical compositions comprising said chimeric protein and use thereof.Type: GrantFiled: June 28, 2005Date of Patent: January 29, 2013Assignee: Yeda Research and Development Co. Ltd.Inventors: David Wallach, Elena Appel, Tanya Goncahrov
-
Publication number: 20130022582Abstract: The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.Type: ApplicationFiled: October 22, 2010Publication date: January 24, 2013Applicants: CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES, SERVICIO ANDALUZ DE SALUD, HOSPITAL CLINIC DE BARCELONAInventors: Simón Méndez Ferrer, Álvaro Urbano Ispizua
-
Publication number: 20130017600Abstract: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells, after exposure to a prostate cancer antigen or specific antigenic peptide, are administered to a prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro. The activated T cells are then administered to a prostate cancer patient. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.Type: ApplicationFiled: June 14, 2012Publication date: January 17, 2013Applicant: NORTHWEST BIOTHERAPEUTICS, INC.Inventors: Gerald P. Murphy, Alton L. Boynton, Benjamin A. Tjoa
-
Publication number: 20130017175Abstract: Inflammatory cytokines e.g. IFN-?, serve as initiating stimuli for mesenchymal stem cell (MSC) immunosuppresive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC, may also provide such a response. Activated MSC's promote tissue regeneration in conditions such as aging, where regeneration is impaired. Wound healing in aged mammals was enhanced by restoring tensile strength to the levels of younger mammals. Activated MSCs were useful in treating wounds in diabetic primates.Type: ApplicationFiled: May 30, 2012Publication date: January 17, 2013Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Amelia Bartholomew, Simon Lee, Erzsebet Szilagyi
-
Publication number: 20130017151Abstract: Compositions and methods for generating dendritic cell (DC)-targeting vaccines against vaginal infections, including but not limited to sexually transmitted diseases, are disclosed herein. The present invention reports the isolation of at least four major subsets of myeloid-originated antigen-presenting cells (APCs) that possess distinct phenotypes and functions in directing immune responses, namely, Langerhans cells (LCs: E-cadherin+CD207+CD205+), CD1c+CD14? DCs (DC-ASGPR+CD209+/?Dectin-1+/?), and CD1c+CD14+ DCs (CD209+/?DC-ASGPR+/?) all expressing high levels of CD11c, CD83, and CCR6, and are more potent than CD1c?CD14+ macrophages (CD163+CD209+DC-ASGPR+/?Dectin-1+/?LOX-1+CD1d+) at eliciting naïve T cell proliferation The compositions, methods and vaccines of the present invention are directed towards the four functionally distinct major subsets of antigen-presenting cells (APCs) that can differentially contribute to the host immune response in the female genital tract, including the vagina.Type: ApplicationFiled: July 11, 2012Publication date: January 17, 2013Applicant: BAYLOR RESEARCH INSTITUTEInventors: SangKon Oh, Dorothee Duluc, Julien Gannevat
-
Patent number: 8354275Abstract: A method of inducing dendritic cell (DC) development by administering Macrophage-Colony Stimulating Factor is provided. M-CSF induces DCs to differentiate into subtypes, for example plasmacytoid DCs and conventional DCs. Induction with M-CSF can be achieved in vitro from hematopoietic precursors, such as bone marrow cells, or in vivo. In vitro, M-CSF-derived DCs can be used to produce cytokines and to stimulate other immune response cells. M-CSF can also be used to induce precursor cells removed from an animal to develop into DCs. In addition, these isolated DCs can be exposed to antigens to stimulate a specific immune response when reintroduced into the animal. Treatments for cancers, such as Acute Myeloid Leukemia, and autoimmune diseases such as Systemic Lupus Erythematosus, are also provided in the invention.Type: GrantFiled: September 21, 2011Date of Patent: January 15, 2013Assignee: Bavarian Nordic A/SInventors: Hubertus Hochrein, Meredith O'Keeffe
-
Patent number: 8349810Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain, as well as polynucleotides encoding same. Fusion proteins comprising cleavage half-domains are used in pairs to reconstitute a functional cleavage domain. In these fusion proteins, the zinc finger domain can be N-terminal to the cleavage half-domain, or the cleavage half-domain can be N-terminal to the zinc finger domain.Type: GrantFiled: June 22, 2011Date of Patent: January 8, 2013Assignee: Sangamo BioSciences, Inc.Inventors: Jeffrey C. Miller, Lei Zhang
-
Publication number: 20130004432Abstract: Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.Type: ApplicationFiled: December 8, 2010Publication date: January 3, 2013Inventors: Michel Pierres, Eric Vivier, Myriam Baratin
-
Patent number: 8343485Abstract: The present invention relates to pharmaceutical compositions comprising a chemotactic hematopoietic stem cell product comprising an enriched population of CD34+ cells containing a subpopulation of CD34+/CXCR-4+ cells having CXCR-4-mediated chemotactic activity, methods of preparing these compositions and use of these compositions to treat or repair vascular injury, including infarcted myocardium.Type: GrantFiled: December 6, 2011Date of Patent: January 1, 2013Assignee: Amorcyte, Inc.Inventors: Andrew L. Pecora, Robert A. Preti
-
Publication number: 20120329153Abstract: This invention relates to methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention relates to methods and compositions for modulating movement of CaR receptor expressing cells of hematopoietic, neural, epithelial, endothelial, or mesenchymal origin, in a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to modulate migratory-cell movement associated with specific sites in a subject. Specific sites include sites of inflammation and modulation of migratory-cell movement is movement away from an agent source, or repulsion. The invention also relates to methods for manipulating io hematopoeitic progenitor cells and related products.Type: ApplicationFiled: May 30, 2011Publication date: December 27, 2012Applicant: THE GENERAL HOSPITAL CORPORATIONInventors: Mark C. Poznansky, Edward M. Brown, David T. Scadden, Ivona T. Olszak
-
Publication number: 20120329709Abstract: The present invention provides methods and materials by which glycosylation of glycoproteins can be regulated. Methods include the monitoring and regulation of parameters such that a glycoprotein having a desired product quality is obtained.Type: ApplicationFiled: May 25, 2010Publication date: December 27, 2012Inventors: Brian Edward Collins, Tiffany Guo, Lakshmanan Thiruneelakantapillai, Kevin Millea, Dorota A. Bulik
-
Patent number: 8337833Abstract: Methods of causing an improvement in central nervous system function are provided. The methods include administering an aliquot of stem cells to the patient, the cells being derived from blood, e.g., umbilical cord blood. In some cases a growth factor is administered with the cells.Type: GrantFiled: May 11, 2010Date of Patent: December 25, 2012Assignees: The General Hospital Corp., ViaCord, LLCInventors: Morey Kraus, Seth Finklestein, Paul Clark
-
Patent number: 8338177Abstract: A method for culturing cells in the presence of an alcanoic acid for enhancing protein production.Type: GrantFiled: July 6, 2007Date of Patent: December 25, 2012Assignee: Lonza Biologics PLCInventors: David Mainwaring, Jeremy Wayte
-
Patent number: 8338169Abstract: A cell/ligand specific marking system, the system being characterized in that it comprises: (a) an endothelial precursor cell (EPC) including a cell marker selected from among the group consisting of the Eph (in particular EphB4 or EphB1), and (b) a protein material of structure L-K, which consists of a ligand (L) specific of the marker and is associated or fused with a binding protein (K), the system being capable of providing a proangiogenetic cell material of structure EPC-Eph-L-K. The invention also concerns the cell material as product capable of stimulating angiogenesis, its preparation method and its therapeutic use, in particular with respect to vascular insufficiencies.Type: GrantFiled: July 27, 2006Date of Patent: December 25, 2012Assignees: Institut des Vaisseaux et du Sang, Universite Paris 7-Denis DiderotInventors: Philippe Foubert, Sophie Le Ricousse-Roussanne, Jean-Sebastien Silvestre
-
Patent number: 8338113Abstract: Provided is a method of identifying a trophoblast by detecting in cells of a biological sample, with the proviso that the biological sample does not comprise a placental tissue, expression of a trophoblast marker selected from the group consisting of an annexin IV, a cytokeratin-7, a cytokeratin-8 and a cytokeratin-19; and classifying cells exhibiting expression of the trophoblast marker as trophoblasts. Also provided are methods of detecting a pregnancy in a subject, isolating trophoblasts from biological samples and prenatally diagnosing a conceptus using the identified trophoblasts.Type: GrantFiled: May 1, 2008Date of Patent: December 25, 2012Assignee: Tel HaShomer Medical Research Infrastructure and Services Ltd.Inventors: Esther Guetta, Gad Barkai, Liat Gutstein-Abo
-
Publication number: 20120322152Abstract: The invention relates to methods of culturing and/or proliferating stem cells such as progenitor cells, multipotent and induced pluripotent stem (IPS) cells. More particularly, the invention relates to the use of macromolecular crowding created using carbohydrate-based macromolecule to promote the growth of the stem cells in an ex vivo culture, while preserving their multipotentiality.Type: ApplicationFiled: March 2, 2011Publication date: December 20, 2012Inventors: Michael Raghunath, Hui Li Loe, Anna Blocki
-
Publication number: 20120315643Abstract: Provided are alternative splicing constructs and methods for their use. In particular, CD44 based alternative splicing constructs are provided that include CD44 exon 5. These alternative splicing constructs are useful in high-throughput assays for testing the effects of compounds on splicing and for achieving targeted cell death.Type: ApplicationFiled: May 31, 2012Publication date: December 13, 2012Inventors: Dayle A. Daines, Robert J. McKallip
-
Publication number: 20120315338Abstract: The present invention provides a method of generating megakaryocytes and platelets. In various embodiments, method involves the use of human embryonic stem cell derived hemangioblasts for differentiation into megakaryocytes and platelets under serum and stromal-free condition. In this system, hESCs are directed towards megakaryocytes through embryoid body formation and hemangioblast differentiation. Further provided is a method of treating a subject in need of platelet transfusion.Type: ApplicationFiled: December 3, 2010Publication date: December 13, 2012Applicant: Stem Cell & Regenerative Medicine International, Inc.Inventors: Feng Li, Shi-Jiang Lu
-
Publication number: 20120316114Abstract: The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).Type: ApplicationFiled: May 8, 2012Publication date: December 13, 2012Applicant: BIOMARIN PHARMACEUTICAL INC.Inventors: Daniel J. Wendt, Shinong Long, Sianna Castillo, Christopher P. Price, Mika Aoyagi-Scharber, Michel C. Vellard, Augustus O. Okhamafe
-
Patent number: 8329464Abstract: The present disclosure uses different kinds of surface treatment processes on titanium-made dental implants. The growth and attachment conditions of bone cells (MC3T3-E), fibroblasts (NIH 3T3) and epidermal cells (XB-2) on the metal surface of titanium slices with different surface treatments are observed. Tetra-calcium phosphate is used to perform secondary sand-blasting process to clean up the metal surface and provide calcium ions for osteoblastoma physiology. Thus, by adjusting the cells adhesive and proliferative abilities, the success rate of the clinical applications in dental implant is improved.Type: GrantFiled: September 1, 2010Date of Patent: December 11, 2012Assignee: Kaohsiung Medical UniversityInventors: Wen-Cheng Chen, Chun-Cheng Hung, Chia-Ling Ko
-
Publication number: 20120308607Abstract: The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and yeast systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.Type: ApplicationFiled: July 19, 2012Publication date: December 6, 2012Applicant: Glycotope GmbH.Inventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
-
Publication number: 20120308985Abstract: A composition (and associated methods) including a plurality of treated red blood cells for simulating reticulocytes, and particularly an immature reticulocyte fraction, of whole blood when processed as a sample in an automated analyzer capable of detecting reticulocytes. A method for making the composition or other simulated reticulocyte may include steps of contacting a suspension of a plurality of red blood cells each having a membrane in an initial state that surrounds an interior volume of a cell with an effective amount of a hypertonic permeabilizing solution including dimethyl sulfoxide and a hypotonic loading agent delivery solution including a loading agent, for a sufficient time to form a plurality of pores in the membrane, for permitting the loading agent to enter into the interior volume of the cells.Type: ApplicationFiled: April 20, 2012Publication date: December 6, 2012Applicant: STRECK, INC.Inventors: Wayne L. Ryan, John W. Scholl
-
Patent number: 8323967Abstract: This invention relates to methods and compositions for enhancing hematopoietic stem cell mobilization by inhibiting early growth response-1 (egr1) activity.Type: GrantFiled: April 5, 2007Date of Patent: December 4, 2012Assignee: Joslin Diabetes Center, Inc.Inventors: Amy Wagers, Irene Min
-
Patent number: 8323968Abstract: Osteopontin for the prediction and treatment of cardiovascular diseases The present invention relates to the use of endothelial progenitor cells (EPCs) and osteopontin for the treatment of cardiovascular diseases or complications. The invention also relates to the use of EPC osteopontin levels as a marker of the risk of the development of these cardiovascular complications. In particular, the invention provides compositions and methods based on osteopontin and the genes encoding osteopontin.Type: GrantFiled: March 3, 2008Date of Patent: December 4, 2012Assignee: National University of Ireland, GalwayInventors: Timothy O'Brien, Frank Barry, Aaron Yie Loong Liew, Afshin Samali, Angela Duffy
-
Patent number: 8323965Abstract: Multiple myeloma (MM) is a clonal B cell malignancy and remains essentially incurable by conventional anti-tumor therapy. Patients with MM have a median survival of only three years. MM is characterized by proliferation and accumulation of mature plasma cells in the bone marrow (BM) leading to bone destruction, BM failure, anemia, and reduced immune function. The identification of MHC Class I, HLA-A2, associated peptides presented on multiple myeloma cells is an important step in developing immunotherapies for MM. Presented here are methods for creating activated T lymphocytes that are cytotoxic to both peptide loaded T2 target cells and multiple myeloma cell lines.Type: GrantFiled: October 31, 2011Date of Patent: December 4, 2012Assignee: Janssen Pharmaceutica NVInventors: Zeling Cai, Wei-Xing Shi, Xuejun P. Liu, Jiejun Wu
-
Patent number: 8313945Abstract: Methods are provided for inducing differentiation of blood monocytes into functional antigen presenting dendritic cells. The blood monocytes are treated by exposing the monocytes to proteins adhered to the surface of a treatment device to induce differentiation of the monocytes in to dendritic cells. Differentiation of the monocytes may also be induced by physical perturbation of the monocytes during treatment. The treated monocytes may be co-incubated with disease effector agents, which may be phagocytized by the immature dendritic cells.Type: GrantFiled: May 16, 2007Date of Patent: November 20, 2012Assignee: Yale UniversityInventors: Richard L. Edelson, Carole L. Berger
-
Patent number: 8313943Abstract: The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (Fc?RIII-A), or other Fc? or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as Fc?RI-?, TCR-?, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.Type: GrantFiled: September 22, 2009Date of Patent: November 20, 2012Assignee: Fox Chase Cancer CenterInventor: Kerry S. Campbell
-
Patent number: 8309070Abstract: The invention relates generally to methods for isolation and culture of umbilical cord blood stem cells, cells isolated by the methods, and therapeutic uses for those cells.Type: GrantFiled: May 17, 2005Date of Patent: November 13, 2012Assignee: Regents of the University of MinnesotaInventors: Walter Low, Jing Xiao, Zhenhong Nan
-
Patent number: 8309106Abstract: Tissue repair compositions, particularly bone repair compositions, containing demineralized bone fragments and homogenized connective tissues. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form.Type: GrantFiled: February 27, 2009Date of Patent: November 13, 2012Assignee: Lifenet HealthInventors: Leila Masinaei, Lloyd Wolfinbarger, Jr.
-
Publication number: 20120282693Abstract: This invention provides methods of generating natural killer (NK) cells and dendritic cells (DCs). The methods utilize human hemangioblasts as intermediate cells to generate the NK cells and DCs. In various embodiments, the methods do not require the use of stromal feeder layers.Type: ApplicationFiled: December 1, 2010Publication date: November 8, 2012Applicant: Stem Cell & Regenerative Medicine International, Inc.Inventors: Erin Kimbrel, Shi-Jiang Lu
-
Publication number: 20120276065Abstract: The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby.Type: ApplicationFiled: April 23, 2012Publication date: November 1, 2012Applicant: Miltenyi Biotech GmbHInventors: Juergen Schmitz, Andrzej Dzionek, David William Buck
-
Patent number: 8293530Abstract: A method of making a bioplastic, and a bioplastic produced thereby, by using human plasma in which human plasma is clotted, either dried through its gel phase or dried and powdered, and processed into a bioplastic with the addition of at least one plasticizer followed by forming and heating to form a final bioplastic construct.Type: GrantFiled: October 17, 2007Date of Patent: October 23, 2012Assignees: Carnegie Mellon University, Allegheny-Singer Research InstituteInventors: James E. Burgess, Phil G. Campbell, Lee E. Weiss, Jason Smith
-
Publication number: 20120263685Abstract: The present invention relates to a composition for preventing or treating cancer, which contains one or more selected from the group consisting of human adult stem cells and their secretory products, and to a method of preventing or treating cancer using the same. Particularly, the invention relates to the use of adult stem cells that exhibit the effect of preventing or treating cancer by activating the immune system. The human adult stem cells of the invention are administered by a simple method such as intravenous injection and are highly valuable as a cell therapeutic agent for treating various cancer (tumor) diseases. Thus, the adult stem cells will be highly useful in anticancer studies.Type: ApplicationFiled: April 7, 2010Publication date: October 18, 2012Applicant: RNL BIO CO., LTDInventors: Jeong Chan RA, Sung Keun KANG, Sang Kyu WOO, Hwa Young YOUN, Hee Woo LEE, Kyoung Won SEO
-
Patent number: RE44024Abstract: This invention provides an isolated polynucleotide encoding an ECA1 polypeptide. Also provided is the isolated ECA1 polypeptide Further provided is an antibody that specifically recognizes and binds the ECA1 polypeptide or an epitope thereof. The polynucleotides, antibodies and/or polypeptides of this invention may be components of compositions, host cells and/or gene delivery vehicles, where appropriate. In one aspect, the host cell will produce recombinant ECA1, which is further defined herein. In another aspect, the host cell is an antigen presenting cell such as a dendritic cell, and it will display an antigenic portion of the ECA1 polypeptide on its surface. The polypeptides, proteins and compositions of this invention are useful to aid in the diagnosis of a neoplastic condition of a cell of endometrioid origin.Type: GrantFiled: May 13, 2010Date of Patent: February 19, 2013Assignee: The University of Southern CaliforniaInventors: Michael F. Press, Bahman Saffari